jordan 13 Bristol-myers Squibb Co Pharmavitae Prof

dobso008ag

[link widoczny dla zalogowanych]
Acordis Speciality Fibres

Key findings
Latest quarterly sales
Table of Contents
Bristol-Myers Squibb: PharmaVitae forecasts at a glance
Reasons to Purchase

las [link widoczny dla zalogowanych], TX: ReportsandReports announce [url=/market-reports/bristol-myers-squibb-co-pharmavitae-profile/]Bristol-Myers Squibb Co.: PharmaVitae Profile[/url] Market Research Report in its Store.
Browse complete Report at [url=/market-reports/bristol-myers-squibb-co-pharmavitae-profile/]/market-reports/bristol-myers-squibb-co-pharmavitae-profile/[/url]
This analysis examines the historical and forecast performance for BMS in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance [link widoczny dla zalogowanych], with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Financial performance, 2003-15

Slow growth in cardiovascular disease will be offset by prospects in diabetes

Adnexus Therapeutics

Analyst consensus
M&A history

Assess how BMS is exploring the fast-growth oncology and immunology disease markets to drive long-term sales in the face of blockbuster patent expiry

Sales data
Medarex
Q1 2010

BMS fast evolving into a fully-fledged biopharmaceutical player
SWOT analysis

BMS builds Big Pharma collaborations

ASCO 2010: ipilimumab achieves breakthrough in 'long dark tunnel' of metastatic melanoma
ABOUT DATAMONITOR HEALTHCARE

Q2 2010

Company introduction

Chapter 3 Quarterly news update

Future product milestones

Chapter structure

Strategic insight
About the PharmaVitae team
BMS will focus on areas of high unmet need to mitigate the decline of its CV portfolio
Q1 2010
Productivity transformation initiative expected to lower operating costs by $2.5 billion by 2012

Investigate the strength of BMS's pipeline, its product collaborations with AstraZeneca and Pfizer and the recent acquisition of Medarex.
Table Of Contents
Key findings
Chapter 4 Company introduction
Background

BMS has the second fastest expiry decline within Big Pharma
Bristol-Myers
Kosan Biosciences

PharmaVitae Explorer database
Latest corporate news

Squibb
EASL 2010: promising developments in the hepatitis C pipeline

Chapter 1 About this profile

Increasingly profitable business model makes BMS an attractive M&A target

Table of figures
Key corporate developments

Q3 2010
Q1 2010
Latest prescription pharma product news
Plavix dependency pushes BMS over 2012 patent cliff

Q2 2010
Pfizer collaboration for apixaban

Chapter 2 Executive summary

Key products
ASCO 2010: first-line chronic myeloid leukemia becomes next battleground for Sprycel and Tasigna
Executive summary

Quarterly update

Benchmark Bristol-Myers Squibb's performance against key rivals in the ethical pharmaceutical sector

Company sales
Latest comment

DuPont Pharmaceuticals
Data sourcing
Company financials

Q2 2010

Prescription pharmaceutical sales and growth rate performance, 2003-15

Bristol-Myers Squibb

Antidiabetic collaboration with AstraZeneca